ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 مايو 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

05 مايو 2022 16:01:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 مايو 2022 08:00:04 بحسب Nasdaq GlobeNewswire

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

06 أبريل 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

28 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting

25 مارس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study

25 مارس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments

22 مارس 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Arcutis to Host Investor Day on March 28

21 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 مارس 2022 16:05:00 بحسب Nasdaq GlobeNewswire